Hematology
News
FDA panel rejects rivaroxaban again for acute coronary syndrome
Conference Coverage
Statins reduce recurrent thromboembolism risk
Major finding: Patients on statin therapy had an adjusted 17% lower risk of recurrent venous thromboembolism in the year following their first...
Conference Coverage
In the real world, persistence on warfarin is low
Major finding: Less than one-half of patients with a first VTE started on warfarin within 10 days; of those who did, nearly 75% discontinued...
News
Low event rates with real-world use of rivaroxaban in NOAC
Major finding: The annual stroke rate with once-daily rivaroxaban was 1.4% and the major bleeding rate was 3.4% among 1,194 patients with atrial...
News
Comfort care informs critical care societies’ Choosing Wisely list
News
Genotyping adds little to optimized warfarin dosing
Major finding: Patients starting warfarin with dosing based on a formula that took into account seven clinical and demographic factors averaged 45...
News
Thrombosis precautions in IBD not met in two-thirds of high-risk cases
News
Novel Watchman antistroke device backed as warfarin equivalent
News
VIDEO: What's ahead for chronic myelogenous leukemia?
Conference Coverage
Sickle cell crises curtailed with experimental cellular adhesion inhibitor
Major finding: The mean time to resolution of vaso-occlusive crisis in patients with sickle cell disease was 103 hours for patients treated with...